

Terry L Ng

List of Publications by Citations

Source: <https://exaly.com/author-pdf/539970/terry-l-ng-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38 papers	450 citations	11 h-index	21 g-index
39 ext. papers	604 ext. citations	4.1 avg, IF	3.57 L-index

#	Paper	IF	Citations
38	Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. <i>Oncologist</i> , 2015 , 20, 210-23	5.7	68
37	Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. <i>Science Advances</i> , 2019 , 5, eaav2437	24.37	52
36	Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?. <i>Oncologist</i> , 2015 , 20, 576-83	5.7	50
35	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. <i>Cancer</i> , 2019 , 125, 1038-1049	6.4	39
34	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 596-605	8.9	34
33	Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9010-9010	22.3	33
32	Defining optimal control of chemotherapy-induced nausea and vomiting-based on patientsU experience. <i>Supportive Care in Cancer</i> , 2015 , 23, 3341-59	3.9	31
31	Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 1-8	4.4	22
30	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. <i>Lung Cancer</i> , 2018 , 125, 115-120	5.9	16
29	Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1190-1199	8.9	13
28	Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 337-44	4.4	13
27	Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. <i>Supportive Care in Cancer</i> , 2021 , 29, 925-943	3.9	10
26	Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer--an inspection of the evidence base informing clinical decision-making. <i>Cancer Treatment Reviews</i> , 2015 , 41, 951-9	14.4	9
25	Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits. <i>Current Opinion in Supportive and Palliative Care</i> , 2014 , 8, 420-8	2.6	8
24	Aprepitant versus dexamethasone to prevent delayed emesis after chemotherapy. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2184-5	2.2	7
23	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. <i>Clinical Lung Cancer</i> , 2019 , 20, e39-e51	4.9	7
22	Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey. <i>Journal of Bone Oncology</i> , 2021 , 26, 100339	4.5	7

21	Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. <i>Lung Cancer</i> , 2018 , 126, 112-118	5.9	6
20	Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer. <i>Bladder Cancer</i> , 2019 , 5, 131-145	1	3
19	The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 103540	7	3
18	Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation. <i>Journal of Bone Oncology</i> , 2021 , 27, 100351	4.5	3
17	Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. <i>Supportive Care in Cancer</i> , 2021 , 29, 6903-6912	3.9	3
16	Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer. <i>Journal of Bone Oncology</i> , 2021 , 26, 100343	4.5	3
15	A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. <i>Breast</i> , 2021 , 58, 42-49	3.6	3
14	Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1452-1463	4.4	2
13	Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.. <i>Supportive Care in Cancer</i> , 2022 , 30, 3977	3.9	1
12	A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer.. <i>Current Oncology</i> , 2021 , 28, 5073-5083	2.8	1
11	Skeletal-related events (SRE) and bone-targeted agents for metastatic prostate cancer: Are we changing outcomes?. <i>Journal of Clinical Oncology</i> , 2013 , 31, e16074-e16074	2.2	1
10	A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients. <i>Supportive Care in Cancer</i> , 2021 , 29, 5787-5795	3.9	1
9	Cost-Effectiveness Analysis of 12- Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021 , 28, 1847-1856	2.8	1
8	Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	0
7	Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e24083-e24083	2.2	0
6	Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey.. <i>Current Oncology</i> , 2021 , 28, 5215-5226	2.8	0
5	Early pulmonary function changes associated with brigatinib initiation.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9538-9538	2.2	
4	Is there a role for oral or intravenous ascorbate (vitamin C) treatment for patients with cancer? A systematic review.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20598-e20598	2.2	

- 3 Antiemetic recommendations for breast cancer patients receiving highly emetogenic chemotherapy: A systematic review incorporating network meta-analyses.. *Journal of Clinical Oncology*, **2014**, 32, e17608-e17608 2.2
- 2 Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation. *Journal of Thoracic Oncology*, **2021**, 16, 486-491 8.9
- 1 Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial). *Cancer Research*, **2022**, 82, OT1-01-01-OT1-01-01 10.1